Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases.
A new dosage form consisting of small activated carbon particles which adsorb Aclacinomycin A, Adriamycin, Mitomycin C or Pepleomycin was prepared in order to deliver larger amounts of anticancer agents to the lymph nodes through the high ability of lymphatics to adsorb particles. Animal experiments showed that: The LD50 values of the new dosage form were higher than those of the dosage in solution. The concentration of agents in lymph nodes was maintained at a higher level in the new dosage form than in solution form. Clinically 33% of lymphnodal metastatic lesions became degenerative or inflammatory after a single administration.